The case in front of me: ferritin · oral semaglutide.
I want to decide this in advance so that I am not deciding it under pressure later.
Assume I will follow the plan I write down, so I would like it to be a good one.
How would you structure this, and what thresholds would you set in advance?
Start with a baseline. A result taken before anything started converts most later ambiguity into a simple comparison, and it cannot be obtained retrospectively.
Haemolysis in the sample raises potassium and several enzymes spuriously. If a result is bizarre, ask whether the sample was flagged before building a theory on it.
Timing matters per analyte: cortisol and testosterone are diurnal, triglycerides are postprandial, and creatinine responds to hydration and to recent training. Fixing the conditions removes most of the noise.
Pre-analytical factors — posture, tourniquet time, fasting, sample handling — are the largest source of error in routine biochemistry, well ahead of the analysis itself.
Keep the full report, not the number. You will need the units and the interval later.
Aggregated, published test results and vendor ratings built from submitted batches. Methodology stated, dataset browsable, no listing fees.
Browse resultsAnswer first: decide what you would do differently for each possible result before you order the panel. Anything that fails that test is a number you will worry about and not act on.
Same laboratory, same method, same time of day, same fasting state. Between-laboratory differences on several common analytes are larger than the changes people are trying to detect.
Keep the reports rather than the numbers. Units, reference intervals and methods all vary, and a bare number two years later is not comparable to anything.
Reference intervals are conventionally the central ninety-five per cent of a reference population, which is the direct cause of the one-in-twenty out-of-range rate on a healthy panel.
One out-of-range value on a twenty-analyte panel is expected. Two on a repeat is a finding.
edited 21 Aug 2024 by Dr_Nadia_Farsi — reworded for clarity after a comment
Answering this needs to distinguish screening from monitoring. A screening panel looks for the unexpected; a monitoring panel tracks something you already have a reason to watch.
Repeat before you react. A single abnormal value has a substantial probability of being within the combined biological and analytical variation of a normal one.
Delta checks — comparing against your own previous value — are far more sensitive than comparing against a population interval, which is the argument for keeping a series rather than a snapshot.
Nothing here is medical advice. If something is out of range and you do not know why, that is a consultation rather than a research project.
Baseline first, then a repeat under identical conditions. Everything else is secondary.
This is answerable, and the answer is mostly about which tests rather than how many.
A sensible core for this population is a full blood count, renal function with electrolytes, liver enzymes with bilirubin, a fasting lipid panel with apolipoprotein B, HbA1c and thyroid-stimulating hormone.
Biological variation data are published per analyte and are the basis for the reference change value — the difference between two results that is larger than noise.
Same laboratory, same time, same fasting state, or the comparison is not a comparison.
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.